Asthma has been increasingly recognized as a heterogeneous disease; however, many patients with asthma suffer from allergic asthma. While inhaled corticosteroids and other inhalers have been integral in treating many symptoms of asthma, these medications do not completely address the underlying mechanism of the disease. Pediatric asthma imposes a substantial burden on patients and the healthcare system. Omalizumab is consistently recognized as an important consideration for add-on therapy in pediatric patients with allergic asthma in published guidelines from multiple international societies such as the Global Initiative for Asthma. Since our last report in 2017, the amount of information available regarding the safety and effectiveness of omalizumab in pediatric patients with allergic asthma has continued to accumulate and is supported by several observational and real-world data studies. A number of studies including real-world effectiveness studies, post-hoc analyses of clinical trial data, and systematic literature reviews and meta-analyses have since expanded the published data on the efficacy and safety of omalizumab in pediatric patients. In this article, we present an updated review of this literature focused on use of omalizumab therapy in children with allergic asthma.

中文翻译：

---

使用奥马珠单抗治疗不受控制的小儿过敏性哮喘的最新综述。


哮喘越来越被认为是一种异质性疾病;然而，许多哮喘患者患有过敏性哮喘。虽然吸入皮质类固醇和其他吸入器在治疗哮喘的许多症状中是不可或缺的，但这些药物并不能完全解决疾病的潜在机制。小儿哮喘给患者和医疗保健系统带来了沉重的负担。奥马珠单抗在多个国际学会（如全球哮喘倡议）发布的指南中一直被认为是过敏性哮喘儿科患者附加治疗的重要考虑因素。自 2017 年上一份报告以来，有关奥马珠单抗在儿科过敏性哮喘患者中的安全性和有效性的可用信息量不断积累，并得到了多项观察性和真实世界数据研究的支持。此后，许多研究，包括真实世界有效性研究、临床试验数据的事后分析以及系统的文献综述和荟萃分析，扩展了已发表的关于奥马珠单抗在儿科患者中疗效和安全性的数据。在本文中，我们介绍了该文献的最新综述，重点是奥马珠单抗治疗过敏性哮喘儿童的使用。